Introduction

During development of new anti-cancer drugs, methods to assess early treatment effect and discriminate between responders and non-responders are widely needed. The use of positron emission tomography (PET) to discriminate between responders and non-responders early following treatment initiation is desirable. The PET technique allows for non-invasive characterization of biological functionality in tumor tissue. 3′-deoxy-3′-[18F]fluoro-3′-fluorothymidine ([18F]FLT) is used to assess cell proliferation in vivo by PET, by measuring the activity of thymidine kinase 1 (TK1) which is up-regulated in the S-phase of cell cycle [1–6]. Uptake of [18F]FLT and [18F]FDG to image treatment effect early following treatment with APO866 in future clinical studies.
[18F]FLT has in several pre-clinical models been shown to decrease following treatment with various chemotherapeutics much earlier than a response in tumor volume is evident [7–16]. However, changes in [18F]FLT uptake following treatment are variable and dependent upon mode of action for the different chemotherapeutic drugs [7,9–11,13].

APO866 is a new anti-tumor compound which inhibits nicotinamide phosphoribosyltransferase (NAMPT), an enzyme involved in the biosynthesis of NAD. APO866 inhibits biosynthesis of cellular NAD from niacinamide by inhibiting NAMPT. Reduction in cellular NAD levels leads to ATP depletion and apoptosis [17,18]. Cancer cells have a high NAD turn over compared with normal cells. NAD is an important cofactor for poly(ADP-ribose) polymerase 1 (PARP1) which is involved in DNA repair and therefore cancer cells are more sensitive to NAMPT inhibition than normal cells. APO866 has anti-tumor effect in many tumor cells in vivo and several pre-clinical human xenograft tumor models [19,20]. A clinical phase I study with APO866 has already been conducted [21], and APO866 is currently in several clinical phase II studies.

APO866 treatment decreases cellular ATP content [17,19] and ATP is a cofactor for TK1 [22]. We therefore hypothesized that [18F]FLT uptake would be influenced by APO866 treatment due to the decrease in ATP and possibly a change in tracer uptake could be used to predict treatment response at an early stage.

2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) has in several pre-clinical and clinical studies been tested for its ability to assess early effect of chemotherapeutics; however, with variable results. When new anti-cancer drugs are brought into clinical phase II and III studies, effective methods to discriminate between responders and non-responders are of great value. The aim of this study was therefore non-invasively to study the effect of APO866 treatment on [18F]FLT and [18F]FDG uptake and to evaluate if [18F]FLT or [18F]FDG PET could be used to monitor early effects of APO866 treatment.

Materials and Methods

Tumor Model

Animal care and all experimental procedures were performed under the approval of the Danish Animal Welfare Council (2006/ 561–1124). Female NMRI (Naval Medical Research Institute) nude mice (6–8 weeks old) were acquired fromTacomeic (Lille Skensved, Denmark) and allowed to acclimatize for one week in the animal facility before any intervention was initiated. The human ovarian carcinoma cell line A2780 [23] (a gift from R. Ozols, Fox Chase Cancer Center Philadelphia, PA, USA) was used. A total of 10^5 cells in 100 μL medium mixed with 100 μL Matrigel™ Basement Membrane Matrix (BD Biosciences, San Jose, CA, USA) were injected subcutaneously into the left and right flank respectively during anesthesia with 1:1 v/v mixture of Hypnorm® and b-CD and 9% propylene glycol at a dose of 15 mg/kg IP twice daily for 7 days. This is the maximum tolerated dose of APO866 and inhibits growth of the A2780 xenograft tumor model [20]. The control groups received vehicle twice daily for 7 days. The mice were scanned at baseline before treatment start with [18F]FLT or [18F]FDG and subsequently [18F]FLT or [18F]FDG scans were repeated at 24 h (Day 1), 48 h (Day 2) and 168 h (Day 7) hours after start of treatment with either APO866 or vehicle. Tumor volume was followed by microCT during the experiments [24–26]. In addition to the microCT measurement of tumor volume, tumor sizes were followed by external caliper measurements where tumor volume was calculated using the modified ellipsoidal formula \( V = \frac{4}{3}\pi \frac{a \times b \times c}{2} \). At Day 7 tumors were excised and transferred to −80°C for Ki67 immunohistochemistry analysis. All tumors were weighted and tumor weight was correlated with both microCT and caliper determined tumor volume.

Synthesis of [18F]FLT and [18F]FDG

[18F]FLT was synthesized using 3-N-Boc-1-[5-O-(4,4’-dimethoxytrityl)-3-O-nosyl-2-deoxyb-D-lyxofuranosyl]thymine as precursor on a GE TracerLab MX Synthesizer as described earlier [7]. All reagents and [18F]FLT cassettes were purchased from ABX (Radeberg, Germany). [18F]FDG was acquired from daily productions for clinical use (Rigshospitalet, Copenhagen, Denmark).

MicroPET and microCT Imaging

Mice were injected i.v. with 10.3±1.4 (mean±SD) MBq [18F]FDG or 9.5±0.9 (mean±SD) MBq [18F]FLT. Mice were fasted overnight before each [18F]FDG scan [27]. One hour after tracer injection mice were anaesthetized with 3% sevoflurane (Abbott Scandinavia AB, Solna, Sweden) mixed with 35% O2 in N2 and fixed on a bed in presence of three fiducial markers allowing fusion of PET and CT pictures. A 10 min PET scan was acquired using a MicroPET Focus 120 (Siemens Medical Solutions, Malvern, PA, USA). After data acquisition, PET data were arranged into sinograms and subsequently reconstructed with the maximum a posteriori (MAP) reconstruction algorithm. The pixel size was 0.866×0.866×0.796 mm and in the center field of view the resolution was 1.4 mm full-width-at-half-maximum. The images were not corrected for attenuation or scatter.

Following the microPET scan, a microCT scan was acquired with a MicroCAT® II system (Siemens Medical Solutions). A 7 minute and 10 seconds CT scan was performed with parameter settings: 360 rotation steps, tube voltage 60 kV, tube current 500 μA, binning 4 and exposure time 310 ms. The pixel size was 0.091×0.091×0.091 mm.

PET and microCT images were fused in the Inveon software (Siemens Medical Solutions). Before fusion region of interests

![Figure 1. Chemical structure of the nicotinamide phosphoribosyltransferase inhibitor APO866.](image-url)

doi:10.1371/journal.pone.0053410.g001
(ROIs) were drawn on the CT pictures manually by qualitative assessment covering the whole tumors and subsequently tumor volume and tracer uptake, assessed by standard uptake values (SUV) mean and maximum, were generated by summation of voxels within the tomographic planes. SUV was defined as \( \text{SUV} = \frac{C_r}{C_{r,0}} \), where \( C_r \) is radioactivity in the tissue, \( C_{r,0} \) is weight of the animal and \( D_{nij} \) is injected dose. SUV mean gives information of the mean concentration of tracer and SUV max is a measure of the voxel within the ROI which have the highest tracer concentration. For tumor volume measurements ROIs were drawn manually by delineation of the tumor boundary by qualitative assessment in several of the coronal planes on the microCT images. Summation of voxels from all the planes generated the tumor volume.

**Ki67 Immunohistochemistry**

After freezing at \(-80\) °C tissue samples were fixed in 4% neutral buffered formalin and subsequently embedded in paraffin. The anti-human Ki-67 clone MIB-1 (Dako cat.no F7268/FTC conjugated mouse antibody) was used. The reactions were detected using standard polymer technique with few modifications. Negative controls were performed by omission of primary antibody. Sections were dewaxed in xylene, rehydrated and pretreated before immunostaining. The slides were incubated with MIB-1 1:100 diluted in Power Block solution (BioGenex, cat. no. HK085-5K) for 30 min at room temperature. The sections were rinsed in TBST (3x5 minutes) and incubated with rabbit anti-FTC (Invitrogen, cat. no. A6413 1:250) for 20 min at RT. The reactions were detected with Super Sensitive polymer-HRP reagent (Biogenex, cat. no. QD410D-XCX) and visualised with DAB ImmPACT Substrate chromogen solution (Vector laboratories cat. co. SK-4105) following the manufactures instructions. Finally, slides were counterstained with Mayer’s haematoxylin.

The level of Ki67 present in the samples was measured as mean of three hot spots on one slide from each tumor. Hotspots were defined as areas with the highest Ki67 intensity and were identified by scanning the entire tumor slide in 10 × magnification. Positive and negative controls from human tissue were placed on each slide for validation of the Ki67 staining index was defined as the number of Ki67 positive cells divided by the total number of tumor cells in an area on the 60 × magnification. Positive and negative controls from human tissue were placed on each slide for validation of the immunohistochemical procedure.

**Statistical Analysis**

Comparison of tumor volume between the treatment and control group were calculated using an unpaired student’s t-test. For intra-group comparisons of tracer uptake ANOVA with Bonferroni post-hoc test was used. All data were tested to be normal distributed by means of Kolmogorov-Smirnov test. Correlations between SUV max ratios and tumor growth were calculated using linear regression. Calculations were made in PASW 17.0 (IBM, Armonk, NY, USA). Data are reported as mean ± SEM (unless stated otherwise) and P < 0.05 was considered statistically significant.

**Results**

**Tumor Growth of APO866 and Vehicle Treated A2780 Xenografts**

Tumor weight correlated with tumor volume determined by microCT \( P < 0.001; r^2 = 0.98 \) and caliper \( P < 0.001; r^2 = 0.87 \) (figure 2). APO866 treatment inhibited growth of A2780 xenograft tumors. Tumors treated with APO866 had volumes (mean ± SEM) that were 114.5 ± 5% (24 h), 128 ± 6% (48 h) and 130 ± 22% (Day 7) relative to baseline volumes at Day 0. In the control group tumor volumes (mean ± SEM) were 118 ± 4% (24 h), 145 ± 6% (48 h) and 339 ± 51% (Day 7) relative to baseline volumes Day 0. Tumor volume between the treatment and control group was significantly different at Day 7 \( P = 0.001 \) (figure 3).

**Changes in [18F]FLT and [18F]FDG Following Treatment Initiation with APO866**

Baseline levels of [18F]FLT uptake measured as SUV mean were 1.26 ± 0.16 (mean ± SD) and SUV max were 2.18 ± 0.20 (mean ± SD). Baseline levels of [18F]FDG uptake measured as SUV mean were 0.67 ± 0.14 (mean ± SD) and SUV max were 1.23 ± 0.29 (mean ± SD).

Uptake of [18F]FLT measured as SUV mean in the APO866 group was 1.28 ± 0.03 at baseline, 0.98 ± 0.03 at 24 h, 0.90 ± 0.03 at 48 h and 0.96 ± 0.07 at Day 7. Compared to baseline [18F]FLT SUV mean was significantly decreased at 24 h \( P < 0.001 \), 48 h \( P < 0.001 \) and Day 7 \( P < 0.001 \) in the APO866 group. No significant changes in [18F]FLT SUV mean were observed in the control group. [18F]FLT SUV max uptake in the APO866 group was 2.20 ± 0.03 at baseline, 1.64 ± 0.04 at 24 h, 1.49 ± 0.03 at 48 h and 1.54 ± 0.11 at Day 7. Compared to baseline [18F]FLT SUV max was significantly different at 24 h \( P < 0.001 \), 48 h \( P < 0.001 \) and Day 7 \( P < 0.001 \) in the APO866 group (figure 4 and 5). No significant changes in [18F]FLT SUV max were observed in the control group.

Uptake of [18F]FDG measured as SUV mean in the APO866 group was 0.70 ± 0.04 at baseline, 0.62 ± 0.03 at 24 h, 0.59 ± 0.04 at 48 h and 0.40 ± 0.08 at Day 7. Compared to baseline [18F]FDG SUV mean was significantly decreased at Day 7 \( P < 0.001 \) in the APO866 group. No significant changes in [18F]FDG SUV mean were observed in the control group. [18F]FDG SUV max uptake in the APO866 group was 1.29 ± 0.09 at baseline, 1.11 ± 0.07 at 24 h, 1.08 ± 0.09 at 48 h and 0.77 ± 0.15 at Day 7. Compared to baseline [18F]FDG SUV max was significantly decreased at Day 7 \( P = 0.005 \) in the APO866 group. In the control group [18F]FDG SUV max was 1.16 ± 0.07 at baseline, 0.91 ± 0.03 at 24 h \( P = 0.007 \) vs. baseline,

**Figure 2. Determination of tumor volume by microCT and caliper.** Comparison of tumor weight and tumor volume determined by microCT and caliper respectively (\( N = 34–35 \) tumors). An identity line is included in the graph. After the last PET scan the tumors were excised and weighed and tumor weight was correlated with the microCT determined tumor volume measured on Day 7 \( P < 0.001 \). Identiﬁcations of tumor volume measured on Day 7 \( P < 0.001 \); \( r^2 = 0.87 \). doi:10.1371/journal.pone.0053410.g002

Changes in [18F]FLT and [18F]FDG Following Treatment Initiation with APO866
1.12 ± 0.04 at 48 h and 1.47 ± 0.05 at Day 7 (P < 0.001 vs. baseline) (figure 4 and 5).

Correlations between SUVmax ratios, from baseline to 24 h, 48 h and Day 7 respectively, and tumor volume changes from baseline to Day 7 for the individual tumors were calculated. For
both [18F]FLT and [18F]FDG no significant correlation was found between SUVmax ratio 24 h/0 h and final tumor growth. [18F]FLT SUVmax ratio 48 h/0 h (P = 0.036; r² = 0.44) and d7/d0 (P = 0.003; r² = 0.69) correlated significantly with final tumor growth and [18F]FDG SUVmax ratio 48 h/0 h (P = 0.031; r² = 0.46) and d7/d0 (P = 0.0024; r² = 0.70) correlated significantly with final tumor growth (figure 6).

Ki67 Immunohistochemistry
Expression of Ki67 protein measured by immunohistochemistry showed a significant correlation with [18F]FLT SUVmean (r² = 0.75; P<0.001). Differences in expression of Ki67 protein between the treatment (28.3%) and control group (52.5%) were significant (P = 0.022) (figure 7). Some of the treated tumors had 0% Ki67 protein expression. Treatment with APO866 for 7 days resulted in no observable Ki67 positive cells in the slides for these tumors.

Discussion
In this study we investigated the effect of APO866 treatment on tumor uptake of [18F]FLT and [18F]FDG by PET in the A2780 ovarian cancer tumor model. By groups, uptake of [18F]FLT decreased after initiation of treatment and was significantly different from baseline already at 24 hours after treatment initiation. By groups, uptake of [18F]FDG did not change on
the first 1–2 days following treatment start, however at Day 7 uptake was significantly decreased to 50% of baseline uptake. At Day 7 we observed decreases in both [18F]FLT and [18F]FDG tracer uptake. On the PET images (figure 5) it was more easy to see the differences between baseline and Day 7 on the [18F]FDG images than on the [18F]FLT images. [18F]FDG is a more widely available tracer than [18F]FLT and therefore the use of [18F]FDG for detection of later treatment effects on Day 7 can be useful.

A measure of the maximal tracer uptake is often used when assessing treatment responses rather than the mean tracer uptake [28]. With SUVmax the most active metabolic region of the tumor is measured, and one advantage of this is that some of the volume delineation problems often found in SUVmean values is
overcome. Much discussion has centered about if inhibiting the most active metabolic or proliferative regions with the anti-cancer treatment is likely to give the best treatment effect. Maximal uptake values are in several studies shown to be a prognostic factor for outcome [28–32]. In the present study we found that changes in SUVmax following treatment correlated better with later tumor volume effect than changes in SUVmean. Furthermore, we found a much greater decrease in [18F]FLT SUVmax values at Day 7 compared to SUVmean values.

Lower uptake of tracer at Day 7 compared to baseline for both [18F]FLT and [18F]FDG in the treatment groups was most likely not due to partial volume effect because of a decrease in tumor volume as the tumors did not shrink during the treatment. The changes in tracer uptake were therefore assumed to be due to physiologic changes in the tumor tissue which were further confirmed by the difference in the quantity of Ki67 positive cells between the treatment and control groups. Positive correlation between [18F]FLT uptake and the amount of Ki67 positive cells have earlier been reported by others [33–36].

APO866 is a relatively slow acting anti-cancer drug without any immediate cytotoxicity leading to ATP depletion and apoptosis [17,19]. Since ATP is a co-factor for TK1, a decrease in ATP level will possibly decrease uptake of [18F]FLT, and a change in ATP tumor level is likely to account for some of the [18F]FLT changes we found in this study. This may also explain why we observed earlier changes in [18F]FLT compared to [18F]FDG. Tumor ATP level is decreased 72 hours after treatment start with APO866 [19]. However, already at 24 hours after treatment start a decrease in NAD content was observed. The early change in NAD levels may contribute to the change in [18F]FLT tracer uptake we found already 24 hours after treatment start in this study. No studies have yet analyzed the level of ATP in mouse tumor models following treatment with APO866 and more experiments are accordingly needed in order to elucidate the exact mechanism behind the decreased [18F]FLT and [18F]FDG uptake following treatment with APO866.

Anti-cancer drugs being cytostatic or having low cytotoxicity often require long treatment time before exerting their effect on tumor volume. The advantage of measuring physiological changes as we do in this study with [18F]FLT and [18F]FDG PET compared to the tumor volume criteria is that we are able to measure a treatment effect earlier than we can measure a change in tumor volume.

When the tumors were studied individually, we found a significant positive correlation between the changes in SUVmax for both [18F]FLT and [18F]FDG between baseline and 48 hours and the tumor growth. Accordingly, those tumors which had the greatest decrease in SUVmax values for both [18F]FDG and [18F]FLT 48 hours after treatment initiation were those which had the lowest increase in tumor volume at the end of the experiment. It indicates that we, in addition to finding a decrease in the whole treatment groups, on the individual tumor level already at 48 hours after treatment initiation were able to identify the tumors that responded best to the treatment as it were those that had the greatest change in SUVmax values.

In conclusion, we found a decrease in tumor [18F]FLT uptake following treatment with the nicotinamide phosphoribosyltransferase inhibitor APO866. After 7 days of treatment tumor uptake of [18F]FDG was half of baseline uptake. Additionally, we found that the tumors which responded best to the treatment were those that had the greatest change in both [18F]FLT and [18F]FDG at 48 hours after treatment initiation. These results show the possibility to use [18F]FLT and [18F]FDG to image treatment effect early following treatment with APO866 in future clinical studies.

Author Contributions
Conceived and designed the experiments: MMJ KDE FB PB LH MS AK. Performed the experiments: MMJ KDE CBJ JM MB. Analyzed the data: MMJ KDE AK. Written the paper: KDE CBJ PB JM MB PB LH MS AK.

References
1. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, et al. (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4: 1334–4.
2. Kong XB, Zhu QY, Vidal PM, Watanabe KA, Polsky B, et al. (1992) Comparisons of anti-human immunodeficiency virus type 1 cell fusion, cellular transport, and plasma and intracellular pharmacokinetics of 3’-thioo-3’-deoxythymidine and 3’-azido-3’-deoxythymidine. Antimicrob Agents Chemother 36: 808–16.
3. Arner ES, Eriksson S (1995) Mammalian deoxyribonucleoside kinases. Pharmacol Ther 67: 155–86.
4. Sherley JL, Kelly TJ (1988) Regulation of human thymidine kinase during the cell cycle. J Biol Chem 263: 8350–8.
5. Raey JS, Grierson JR, Wiese LW, Kolb PD, Schwartz JL (2002) Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 43: 1210–7.
6. Barthel H, Perumal M, Latigo J, He Q, Brady F, et al. (2005) The uptake of 3’-deoxy-3’-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase-1 protein levels. Eur J Nucl Med Mol Imaging 32: 257–63.
7. Jensen MM, Erichen KD, Bjorkling F, Madsen J, Jensen PB, et al. (2010) Early detection of chemoradioresponse in esophageal carcinoma by 3’-deoxy-3’-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res 16: 4500–7.
8. Brerods L, Stroobants S, Verhoof G, De GT, Mortelmans L, et al. (2009) 18F-FLT and 18F-FLT Uptake Early After Cyclophosphamide and mTOR Inhibition in an Experimental Lymphoma Model. J Nucl Med 50: 1102–9.
9. Molhoff CF, Klabbers BM, Beskow J, Velten JT, van GM, et al. (2007) Monitoring response to radiotherapy in human squamous cell cancer bearing nude mice: comparison of 2’-deoxy-2’-[18F]fluoro-D-glucose (FDG) and 3’-[18F]fluoro-3’-deoxythymidine (FLT). Mol Imaging Biol 9: 340–7.
10. Oyama N, Ponde DE, Dence C, Kim J, Tai YC, et al. (2004) Monitoring of growth of chronic myelogenous leukemia cells. Cancer Res 64: 1057–62.
11. Waldherr C, Mellinghoff IK, Tran C, Halpern BS, Rozengurt N, et al. (2005) Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3’-deoxy-3’-18F-fluoro-thymidine PET. J Nucl Med 46: 114–20.
12. Apisarnthanaras C, Alauddin MM, Mourtada F, Ariga H, Raju U, et al. (2006) FK866, a highly specific noncompetitive mTOR inhibitor, decreases the intracellular nicotinamide phosphoribosyltransferase activity and cell cycle. J Biol Chem 263: 8350–8.
13. Wosikowski K, Mattern K, Schemainda I, Hasmann M, Rattel B, et al. (2002) Monitoring response to experimental chemotherapeutic Top216 with [18F]FLT uptake as a measure of thymidine kinase activity in A549 carcinoma cells. J Nucl Med 43: 1210–7.
14. Hasmann M, Schernaida I (2003) PK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 63: 7436–42.
15. Wosikowski K, Mantern K, Schernaida I, Hasmann M, Rattel B, et al. (2002) Monitoring response to experimental chemotherapeutic Top216 with [18F] FLT uptake as a measure of thymidine kinase activity in A549 carcinoma cells. J Nucl Med 43: 1210–7.
16. Nakamura A, Attinger A, Aubry D, Greenery P, Ieson C, et al. (2009) The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood 113: 2376–86.
20. Olesen UH, Thougaard AV, Jensen PB, Sehested M (2010) A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor. Mol Cancer Ther 9: 1609–17.

21. Holen K, Salz LB, Hollywood E, Buck K, Hanauske AR (2008) The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs 26: 45–51.

22. Munch-Petersen B, Cloos L, Jensen HK, Tyrsted G (1995) Human thymidine kinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul 35: 69–89.

23. Eva A, Robbins KC, Andersen PR, Srinivasan A, Tronick SR, et al. (1982) Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells. Nature 295: 116–9.

24. Jensen MM, Jorgensen JT, Bindesup T, Kjaer A (2008) Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imaging 8: 16.

25. de Vries CM, Olofsen AM, Chow P, Ray P, et al. (2007) Multimodality imaging of tumor xenografts and metastases in mice with combined small-animal PET, small-animal CT, and bioluminescence imaging. J Nucl Med 48: 295–303.

26. Ishimori T, Tatsui M, Wahl RL (2005) Tumor response assessment is more robust with sequential CT scanning than external caliper measurements. Acad Radiol 12: 776–81.

27. Fueger BJ, Czernin J, Hildebrandt L, Tran C, Halpern BS, et al. (2006) Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med 47: 999–1006.

28. Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 50 Suppl 1: 122S–308.

29. Berghmans T, Dusart M, Paemans M, Hossein-Foucher C, Bavat I, et al. (2008) Primary tumor standardized uptake value (SUVRmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 3: 6–12.

30. Borst GR, Belderbos JS, Boelard R, Cormans EF, De JK, et al. (2005) Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer 41: 1533–41.

31. Downey RJ, Akhurst T, Goren M, Vincent A, Bains MS, et al. (2004) Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 22: 3253–60.

32. Sohn HJ, Yang YJ, Ryu JS, Oh SJ, Im KC, et al. (2008) [18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res 14: 7423–9.

33. Vesselle H, Grierson J, Muiz M, Pagley JM, Schmidt RA, et al. (2002) In vivo validation of 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT) as a proliferation imaging tracer in humans: correlation of [18F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 8: 3315–23.

34. Leyton J, Smith G, Lees M, Perumal M, Nguyen QD, et al. (2008) Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. Mol Cancer Ther 7: 3112–21.

35. Buck AK, Halter G, Schirrmieister H, Kotzerke J, Wurziger I, et al. (2003) Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 44: 1426–31.

36. Francis DL, Freeman A, Vivikis D, Costa DC, Luthra SK, et al. (2003) In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 52: 1602–6.